Coronavirus Research and Innovation
Since our founding, Tulane researchers have been at the forefront of combatting infectious disease.
Latest News
Tulane researchers receive American Heart Association grant to study COVID’s vascular effects
The American Heart Association has awarded Tulane University researchers $940,000 to study how COVID-19 spurs vascular inflammation that may increase risks for blood clots and lingering symptoms of long COVID. Dr. Xuebin Qin, professor of microbiology and immunology at the Tulane National Primate Research Center, will lead a cross-disciplinary team.
Featured Expert
Bob Garry, professor of microbiology and immunology
A leading expert in virology, Bob Garry is part of a team decoding the genome of the coronavirus to determine its origins and how it possibly evolved from bats and pangolins. Garry also has worked extensively to develop rapid diagnostics, vaccines and new therapies for infectious diseases like Lassa virus and Ebola.
Coronavirus Research
Tony Hu, PhD, Weatherhead Presidential Chair in Biotechnology Innovation
Tony Hu is a pioneer in developing advanced diagnostics for personalized medicine. Hu is working to develop highly sensitive blood or saliva tests that rely on nanotechnology to help doctors quickly diagnose COVID-19.
Lina Moses, PhD, assistant professor of epidemiology and disease ecology
Disease ecologist Lina Moses, PhD, is a leading expert in tropical virology. She spent time in Geneva coordinating research efforts for WHO and the Global Outbreak Alert and Response Network.
James “Mac” Hyman, mathematics professor
Mac Hyman is developing mathematical models to better understand and predict the spread of COVID-19. His research provides a methodology to predict the number of new infections five, 10 and 15 days into the future.
Jay Rappaport, PhD, Tulane National Primate Research Center director
Under the direction of Jay Rappaport, Tulane National Primate Research Center is establishing a research program to develop a vaccine for the virus. He is leading a team to create one of the first nonhuman primate models of the disease.